|
1
|
Surh YJ: Cancer chemoprevention with
dietary phytochemicals. Nat Rev Cancer. 3:768–780. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee KW, Bode AM and Dong Z: Molecular
targets of phytochemicals for cancer prevention. Nat Rev Cancer.
11:211–218. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ishihara M, Naoi K, Hashita M, Itoh Y and
Suzui M: Growth inhibitory activity of ethanol extracts of Chinese
and Brazilian propolis in four human colon carcinoma cell lines.
Oncol Rep. 22:349–354. 2009.PubMed/NCBI
|
|
4
|
Morioka T, Suzui M, Nabandith V, Inamine
M, Aniya Y, Nakayama T, Ichiba T, Mori H and Yoshimi N: The
modifying effect of Peucedanum japonicum, a herb in the Ryukyu
Islands, on azoxymethane-induced colon preneoplastic lesions in
male F344 rats. Cancer Lett. 205:133–141. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Morioka T, Suzui M, Nabandith V, Inamine
M, Aniya Y, Nakayama T, Ichiba T and Yoshimi N: Modifying effects
of Terminalia catappa on azoxymethane-induced colon carcino-genesis
in male F344 rats. Eur J Cancer Prev. 14:101–105. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Blum MS, Novak AF and Taber S III:
10-Hydroxy-delta 2-decenoic acid, an antibiotic found in royal
jelly. Science. 130:452–453. 1959. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lerkcer G, Capella P, Conte LS, Ruini F
and Giordani G: Components of royal Jelly: I. Identification of the
organic acids. Lipids. 16:912–919. 1981. View Article : Google Scholar
|
|
8
|
Sugiyama T, Takahashi K and Mori H: Royal
jelly acid, 10-hydroxy-trans-2-decenoic acid, as a modulator of the
innate immune responses. Endocr Metab Immune Disord Drug Targets.
12:368–376. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li X, Huang C and Xue Y: Contribution of
lipids in honeybee (Apis mellifera) royal jelly to health. J Med
Food. 16:96–102. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen YF, Wang K, Zhang YZ, Zheng YF and Hu
FL: In vitro anti-inflammatory effects of three fatty acids from
royal jelly. Mediators Inflamm. 2016:35836842016. View Article : Google Scholar :
|
|
11
|
Yatsunami K and Echigo T: Antibacterial
action of Royal jelly. Bull Fac Agr Tamagawa Univ. 25:13–22.
1985.
|
|
12
|
Alreshoodi FM and Sultanbawa Y:
Antimicrobial activity of royal jelly. Anti-Infective Agents.
13:50–59. 2015. View Article : Google Scholar
|
|
13
|
Sediva M, Laho M, Kohutova L, Mojzisova A,
Majtan J and Klaudiny J: 10-HDA, A major fatty acid of Royal jelly,
exhibits pH dependent growth-inhibitory activity against different
strains of Paenibacillus larvae. Molecules. 23:32362018. View Article : Google Scholar
|
|
14
|
Townsend GF, Morgan JF, Tolnai S, Hazlett
B, Morton HJ and Shuel RW: Studies on the in vitro antitumor
activity of fatty acids. I 10-Hydroxy-2-decenoic acid from royal
jelly. Cancer Res. 20:503–510. 1960.PubMed/NCBI
|
|
15
|
Yang YC, Chou WM, Widowati DA, Lin IP and
Peng CC: 10-hydroxy-2-decenoic acid of royal jelly exhibits
bactericide and anti-inflammatory activity in human colon cancer
cells. BMC Complement Altern Med. 18:2022018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Suzui M: An anticancer agent derived from
natural fatty acid. Chemical Industry. 66:22–27. 2015.In
Japanese.
|
|
17
|
Suzui M and Iinuma M: Anticancer agent.
Japan Patent 5597427. 2014
|
|
18
|
Suzui M, Masuda M, Lim JTE, Albanese C,
Pestell RG and Weinstein IB: Growth inhibition of human hepatoma
cells by acyclic retinoid is associated with induction of p21(CIP1)
and inhibition of expression of cyclin D1. Cancer Res.
62:3997–4006. 2002.PubMed/NCBI
|
|
19
|
Suzui M, Inamine M, Kaneshiro T, Morioka
T, Yoshimi N, Suzuki R, Kohno H and Tanaka T: Indole-3-carbinol
inhibits the growth of human colon carcinoma cells but enhances the
tumor multiplicity and volume of azoxymethane-induced rat colon
carcinogenesis. Int J Oncol. 27:1391–1399. 2005.PubMed/NCBI
|
|
20
|
Suzui M, Sunagawa N, Chiba I, Moriwaki H
and Yoshimi N: Acyclic retinoid, a novel synthetic retinoid,
induces growth inhibition, apoptosis, and changes in mRNA
expression of cell cycle- and differentiation-related molecules in
human colon carcinoma cells. Int J Oncol. 28:1193–1199.
2006.PubMed/NCBI
|
|
21
|
Suzui M, Shimizu M, Masuda M, Lim JTE,
Yoshimi N and Weinstein IB: Acyclic retinoid activates retinoic
acid receptor beta and induces transcriptional activation of
p21(CIP1) in HepG2 human hepatoma cells. Mol Cancer Ther.
3:309–316. 2004.PubMed/NCBI
|
|
22
|
Kawamori T, Rao CV, Seibert K and Reddy
BS: Chemopreventive activity of celecoxib, a specific
cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer
Res. 58:409–412. 1998.PubMed/NCBI
|
|
23
|
Futakuchi M, Nitanda T, Ando S, Matsumoto
H, Yoshimoto E, Fukamachi K and Suzui M: Therapeutic and preventive
effects of osteoclastogenesis inhibitory factor on osteolysis,
proliferation of mammary tumor cell and induction of cancer stem
cells in the bone microenvironment. Int J Mol Sci. 19:8882018.
View Article : Google Scholar :
|
|
24
|
Suzui M, Morioka T and Yoshimi N: Colon
preneoplastic lesions in animal models. J Toxicol Pathol.
26:335–341. 2013. View Article : Google Scholar
|
|
25
|
Bird RP: Observation and quantification of
aberrant crypts in the murine colon treated with a colon
carcinogen: preliminary findings. Cancer Lett. 37:147–151. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kanda Y: Investigation of the freely
available easy-to-use soft-ware 'EZR' for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar
|
|
27
|
Yu H and Jove R: The STATs of cancer-new
molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin Q, Lai R, Chirieac LR, Li C, Thomazy
VA, Grammatikakis I, Rassidakis GZ, Zhang W, Fujio Y, Kunisada K,
et al: Constitutive activation of JAK3/STAT3 in colon carcinoma
tumors and cell lines: Inhibition of JAK3/STAT3 signaling induces
apoptosis and cell cycle arrest of colon carcinoma cells. Am J
Pathol. 167:969–980. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shuai K, Horvath CM, Huang LH, Qureshi SA,
Cowburn D and Darnell JE Jr: Interferon activation of the
transcription factor Stat91 involves dimerization through
SH2-phosphotyrosyl peptide interactions. Cell. 76:821–828. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Weinstock LT, Rost WJ and Cheng CC:
Synthesis of new poly-amine derivatives for cancer chemotherapeutic
studies. J Pharm Sci. 70:956–959. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Carpenter RL and Lo HW: STAT3 target genes
relevant to human cancers. Cancers. 6:897–925. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Reich NC and Liu L: Tracking STAT nuclear
traffic. Nat Rev Immunol. 6:602–612. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fletcher S, Turkson J and Gunning PT:
Molecular approaches towards the inhibition of the signal
transducer and activator of transcription 3 (Stat3) protein. Chem
Med Chem. 3:1159–1168. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pfeffer CM and Singh ATK: Apoptosis: A
target for anticancer therapy. Int J Mol Sci. 19:4482018.
View Article : Google Scholar :
|
|
35
|
Lin L, Hutzen B, Li PK, Ball S, Zuo M,
DeAngelis S, Foust E, Sobo M, Friedman L, Bhasin D, et al: A novel
small molecule, LLL12, inhibits STAT3 phosphorylation and
activities and exhibits potent growth-suppressive activity in human
cancer cells. Neoplasia. 12:39–50. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Song H, Wang R, Wang S and Lin J: A
low-molecular-weight compound discovered through virtual database
screening inhibits Stat3 function in breast cancer cells. Proc Natl
Acad Sci USA. 102:4700–4705. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Baum O, Suter F, Gerber B, Tschanz SA,
Buergy R, Blank F, Hlushchuk R and Djonov V: VEGF-A promotes
intussusceptive angiogenesis in the developing chicken
chorioallantoic membrane. Microcirculation. 17:447–457.
2010.PubMed/NCBI
|
|
38
|
Fenoglio-Preiser CM and Noffsinger A:
Aberrant crypt foci: A review. Toxicol Pathol. 27:632–642. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Di Gregorio C, Losi L, Fante R, Modica S,
Ghidoni M, Pedroni M, Tamassia MG, Gafà L, Ponz de Leon M and
Roncucci L: Histology of aberrant crypt foci in the human colon.
Histopathology. 30:328–334. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nucci MR, Robinson CR, Longo P, Campbell P
and Hamilton SR: Phenotypic and genotypic characteristics of
aberrant crypt foci in human colorectal mucosa. Hum Pathol.
28:1396–1407. 1997. View Article : Google Scholar
|
|
41
|
Shpitz B, Bomstein Y, Mekori Y, Cohen R,
Kaufman Z, Neufeld D, Galkin M and Bernheim J: Aberrant crypt foci
in human colons: Distribution and histomorphologic characteristics.
Hum Pathol. 29:469–475. 1998. View Article : Google Scholar : PubMed/NCBI
|
